The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The FDA has granted 510(k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s ...

The U.S. Food and Drug Administration (USFDA) has cleared for marketing the first in vitro diagnostic device that tests blood ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

The Lumipulse G Plasma Ratio Test offers a new way to detect signs of Alzheimer's disease by identifying plaque proteins in ...

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio enables early detection of amyloid plaques through a non-invasive blood ...

The US Food and Drug Administration has cleared the first-ever blood test for diagnosing Alzheimer's disease, offering a less ...

The FDA cleared the test for the early detection of amyloid plaques associated with Alzheimer’s in people aged 55 years and ...

The test has a complicated name: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. But the goal of the test, created by ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) ...